Seven Mile Advisory Acquires 378 Shares of AstraZeneca PLC (NASDAQ:AZN)

Seven Mile Advisory lifted its holdings in AstraZeneca PLC (NASDAQ:AZN) by 12.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,421 shares of the company’s stock after acquiring an additional 378 shares during the period. Seven Mile Advisory’s holdings in AstraZeneca were worth $267,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in AZN. GHP Investment Advisors Inc. purchased a new stake in AstraZeneca during the 2nd quarter valued at approximately $26,000. Able Wealth Management LLC purchased a new position in AstraZeneca during the fourth quarter valued at $27,000. Pathway Financial Advisers LLC bought a new stake in AstraZeneca in the 1st quarter valued at $29,000. Pin Oak Investment Advisors Inc. lifted its stake in AstraZeneca by 468.4% in the 4th quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock worth $30,000 after purchasing an additional 370 shares in the last quarter. Finally, RFP Financial Group LLC boosted its holdings in shares of AstraZeneca by 56.3% during the 1st quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after purchasing an additional 178 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

AZN has been the topic of a number of research analyst reports. Citigroup upgraded AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. TD Cowen increased their target price on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Argus boosted their price target on shares of AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, May 30th. The Goldman Sachs Group started coverage on shares of AstraZeneca in a research report on Thursday, May 30th. They set a “buy” rating and a $97.00 price objective for the company. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, AstraZeneca presently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Price Performance

AstraZeneca stock opened at $78.27 on Friday. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The firm has a 50-day moving average price of $81.71 and a 200-day moving average price of $76.17. The firm has a market capitalization of $242.68 billion, a PE ratio of 38.37, a price-to-earnings-growth ratio of 1.49 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.01. The business had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.08 earnings per share. As a group, equities research analysts forecast that AstraZeneca PLC will post 4.05 EPS for the current year.

AstraZeneca Cuts Dividend

The firm also recently disclosed a Semi-Annual dividend, which was paid on Monday, September 9th. Shareholders of record on Friday, August 9th were given a $0.49 dividend. This represents a yield of 1.8%. The ex-dividend date of this dividend was Friday, August 9th. AstraZeneca’s dividend payout ratio (DPR) is presently 48.04%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.